Published on
February 11, 2019
In the media
Greywolf bags cash to advance small molecule I-O program
About Greywolf Therapeutics
Greywolf Therapeutics is a clinical-stage biotech company advancing novel antigen modulation technology that controls T cells to guide the immune system. Our approach modulates antigen presentation, flicking a switch inside cells to alter their appearance to the immune system. We are progressing first-in-class antigen modulators to treat people living with cancers, autoimmune disorders, and infectious diseases.
Our lead antigen modulator (GRWD5769) delivered strong results during a phase I/II trial in oncology, demonstrating proof-of-mechanism and target engagement, while our second (GRWD0715) is accelerating through preclinical development as a potential treatment within autoimmunity.
Greywolf is headquartered in Oxford, UK.
More information: Website | LinkedIn
Media enquiries
Patrick White, Head of Communications
